Member Info for PI_Winner

Oldgold22 everyone is entitled to their opinion. I will give you a clue of my DD as to why I believe DT will be acquired this year and I am surprised it has not been picked up on here previously.

There are a couple of rumours within the markets that I am aware of (note I do not deal in rumours so I will not post here in terms of potential parties) in terms of who has acquired the £100M of ML shares that he has recently sold. I will leave it there......

Yep, good RNS update...it all helps and supports the functionality available via DT and future demand for their products and services.

SW it is merely a play on words....google Argentine steaks

Easiwyns you clearly do not understand the market if you do not think that an EY clean bill of health report will move the SP.

Good posts Panda69.....I am impressed. Finally a good relevant healthy debate on here!

I do not necessarily disagree with your viewpoint but unfortunately I align more with the world of reality.

The laws of probability sway more in favour of a takeover given DT has industry leading tech in the AI space, zero debt, cash in the bank, great customer base, excellent customer retention, fantastic products and services etc etc.

In my view the company is seriously undervalued (the Washington Post align to that view) and given DT has been IPO'd, unfortunately the reality is it makes it easier for PE's and monolithic US tech firms to acquire. In the UK the big guys always swallow up the good and the great small guys.....in the world of reality everything has a price acceptable to all parties.

Yep in my view it is a done deal which is great, once that review is complete and published it will materially move the SP as a new tranche of investors will definitely come to the party.

Watchman007 but interested in your point 'there are plenty of reviews where the result is not as intended' Can you share one like for like (apples with apples) example aligned to the DT scenario please to , so that I can have a scan over, obviously not interested in government independent reviews etc. thanks

Watchman007 be in no doubt that EY cannot bury anything identified in the review. My firm view is that EY will not find anything material. Key reasons are:-

1. Since the 1st Feb DT will have undertaken a root and branch review internally
2.RNS 20th Feb - Gordon Hurst, Chair of the Board said: "The Board believes fully in the robustness of Darktrace's financial processes and controls. As a sign of that confidence, we have commissioned this independent third-party review by E&Y. We look forward to the outcome of this review."
Do you think the chair would have made that statement based on a wet finger in the air or based on detailed information????
3. DT were not obligated to pay for and commission an independent review by EY. The only benefit to them is a clean bill of health.

In terms of potential takeover parties. Regarding TB, read the register comments at the time (great source).....verbatim TB stated that they may come back in with another bid. That statement is highly unusual, normally the standard statement from a potential acquirer is the matter is closed and we move on. The register has very good journalists and somebody with loose lips in TB made a strange statement....so TB definitely not out of the picture.

But if you were forcing me to guess where the bid/s would come from I believe it would be another PE or a US tech firm with TB lingering.

I do not believe there will any bids until post the EY final report and a clean bill of health. Sometime after that point would be the time.

That EY report could be more material than the annual results as that will invite a new tranche of investors. But be assured the report will be a clean bill of health from EY with some minor audit control recommendations to portray that they have done their job diligently. All audit reports identify recommendations to identify controls in any organisation, all standard stuff but there will be nothing material. DT will have already played out the same review internally that EY will be performing now.

Thanks Doyezee, good post.

Lets see what happens with takeovers this year. As stated my firm belief is that there will be another takeover attempt in 2023.

I have the very small advantage of working as a consultant in the M&A industry for in the UK financial sector. I am not privy to the inside workings of the US M&A market but I have a fair idea of what attracts takeover attempts/deals etc and based on my experience this ticks all the fundamental boxes and some for a takeover attempt. DT is like a prime Argentinian cow ready to be absorbed.

But lets see, only my opinion of course. DYOR.

No need to worry Pat. Stocks do not go up in a straight line as you know. US and UK economic factors in particular are having a drag on a multitude of stocks at the moment but be assured it will not last. The key point is to watch the trends, a bad day is a 0.5%ish drop for DT versus a good day 3-6% rise on no news. Very good trends in recent weeks on this stock.

In terms of this trading malarchy in order to work we need investors to buy and investors to sell. All investors have different milestones. Even the trend yesterday is good.....close to 280p and then a fall back, it is a good indicator where it is going as opposed to a drop of 10%-15%.

It is not about where you start.....it is where you finish! :)

What to expect:-

EY placeholder date for completion of the review
Heal Test Results, date for release to wider market
Prevent/OT - Uptake in demand
Further AI products in the pipeline/patents
ARR forecasts for the year
% new customers
% customer retention
Detail on further thinking on M&A strategy
Update on buyback scheme
Cash in the bank/Zero debt
Variable - non executive change/s

I am 100% confident it will be a very positive/good news story.

It is inevitable that the SP will ht 300p/350p/400p etc, nobody knows when (although CR888 would disagree!:)) that will be dependent on factors outside of PI's control......materiality of RNS's, market sentiment, economic factors etc etc

DYOR

Thanks Pat.

Jefferies/DT if you are watching......lets ramp this party up a bit!! :) Lets re-think whether we want to throw in a curve ball and ramp up the daily trading to £1M-£2M a day for a period (not a huge increase) to get the juices flowing of the mass herd of PI's.

I think if Wall St was not closed for presidents day we would have had a better uplift in the SP....markets felt muted today....lets see what tomorrow brings.

"Investors are in a wait-and-see mood, with several senior Fed officials scheduled to speak later this week, when January's [Federal Open Market Committee] minutes, containing transcripts of the discussions between senior monetary committee officials, are also due for release," said Ricardo Evangelista, senior analyst at ActivTrades.

The Fed will release its meeting minutes on Wednesday, and its preferred inflation gauge - the core personal consumption expenditures index - will be published on Friday.

Evangelista added that this week's events are expected to offer "more clarity" on the likelihood of a higher-for-longer interest rate scenario with the US central bank. This, he explained, could in turn have a "decisive impact" on the greenback's medium-term direction.

Yep I agree, good post Sheltie

SentinelOne’s operating losses remain LARGE. - Multiple NASDAQ sources

CrowdStrike will also likely remain UNPROFITABLE. - Multiple NASAQ sources

Darktrace also has a resilient business model as demonstrated by the strength of its margins, its significant cash position and ongoing cash generation. Darktrace's current cash position of $368 million has increased by over $100 million since its IPO in May, 2021. - RNS

For FY 2023, Darktrace now expects a year-over-year increase in its constant currency ARR of between 29.0% and 31.5% - RNS

Analysts still expect CrowdStrike's revenue to rise 34% in fiscal 2024, but its slower growth in new customers and net new ARR suggests it will need to squeeze more revenue out of its existing clients to hit that target. - As opposed to sharing links this is widely reported by Nasdaq media, copied and pasted. You will find it in 2 mins. If you look at DT how is it much lower?????

Exactly Watchman, good informed response.

We will get an update on the EY review on the 8th March and when it should be completed. The parameters on their TOR (Terms of reference) should be well defined and I expect it should be completed relatively quickly.

Also be in no doubt that DT would have been doing a wholesale review internally on their accounting practices since the 1st Feb, validating that the forecasts remain in line with 11th Jan RNS and also most importantly before they commissioned the review from EY to ensure there were no 'Gotchas'.

For FY 2023, Darktrace now expects a year-over-year increase in its constant currency ARR of between 29.0% and 31.5% (previously 31% to 34%). This implies a year-over-year change in net ARR added of between (2)% and 6%.

Foreign exchange headwinds present early in the financial year have largely reversed, allowing us to moderate our reduction in revenue expectations. Based on this partial offset to lower ARR growth expectations for FY 2023, Darktrace is now expecting year-over-year revenue growth of between 29.5% and 31.0% (previously 30% to 33%).

These new guidance ranges imply that for FY 2023, Darktrace now expects that 47% to 51% of net ARR added, and 47% to 48% of revenue, will have been contributed in the first half of the financial year.

Based on strong preliminary 1H results, its plans for 2H operations and investment, and its expectation that it will be able to maintain operating efficiencies, Darktrace is increasing its expectations for the FY 2023 adjusted EBITDA margin to between 16.0% and 18.5% (previously 15% to 18%).

Darktrace also has a resilient business model as demonstrated by the strength of its margins, its significant cash position and ongoing cash generation. Darktrace's current cash position of $368 million has increased by over $100 million since its IPO in May, 2021 allowing Darktrace to continue to sufficiently invest in its product pipeline, go-to-market strategy, business foundations and targeted M&A. Darktrace will continue to prioritise investment in its business and the maintenance of appropriate cash reserves.